Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in Food Allergy
NCT05069831Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abrocitinib in food allergy (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: change in basophil activation at 4 months and change in skin prick test at 4 months. Started May 2022; status: completed.
02
Drugs
abrocitinib
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT05069831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069831.